A recent case of a young man requiring bilateral lung transplantation after a severe infection caught my attention. It was widely reported in January 2026. The headlines focused on the remarkable surgical feat: both lungs removed, an artificial lung system sustaining life for 48 hours, and ultimately a successful transplant. Two years later, he is doing well.
But I wasn’t interested in the headline. I was interested in the histology.
I have prepared a presentation on what I call the “COVID trapdoor” — a backdoor entry mechanism that may help explain immune depletion patterns observed during the pandemic. When I read the pathological description of this case, something stood out.
The report described diffuse, uniform destruction across all lung regions, dense infiltration with neutrophils, monocyte-derived alveolar macrophages, activated T cells, marked expansion of myofibroblasts, and near-complete loss of normal alveolar architecture. That is not a simple bacterial pneumonia. Yes, the case referenced a drug-resistant infection. But the pathological pattern described was not focal abscess formation or localized necrosis. It was uniform architectural collapse — an inflammatory and fibrotic takeover of the entire lung.
Yan, Yuanqing, et al. "Bridge to transplant using a flow-adaptive extracorporeal total artificial lung system following bilateral pneumonectomy." Med (2026).
That distinction matters.
To explain what I’ve been working on, I use a simple analogy. Imagine a castle defending itself. The main gate is heavily guarded. That gate represents ACE2 — the well-known receptor SARS-CoV-2 uses to enter cells. Most of the early pandemic discussion centered on that gate. But what if there is a trapdoor? A back tunnel beneath the walls? That trapdoor represents CD147.
ACE2 is not present on many immune cells. CD147 is. If a virus can use CD147 to enter immune cells — particularly CD4+ T cells and B cells — the implications change dramatically. Now the enemy isn’t just breaching the outer wall. It is entering the command center.
Clinicians saw something striking during COVID: low white blood cell counts, depletion of CD4+ T cells, prolonged immune weakness, and severe deterioration in certain patients. CD4+ T cells and B cells do not express ACE2, but they do express CD147. If viral entry can occur via CD147, that offers a plausible mechanism for direct immune cell involvement. Once inside, the situation may worsen. Viral infection may increase CD147 expression, creating more entry points, leading to further infection and amplification of the cycle.
That is not a single breach. It is an amplification loop.
Let’s assume — cautiously — that this young man had SARS-CoV-2 prior to or alongside his bacterial infection. Severe viral infections can disrupt epithelial barriers, weaken immune coordination, and predispose to secondary bacterial pneumonia. But the pathological description in this case points beyond acute infection. It suggests failed resolution biology — inflammation that transitioned into irreversible fibrosis.
If immune depletion occurred first, followed by superinfection, followed by uncontrolled inflammatory repair, the trajectory becomes biologically coherent: viral immune cell depletion, impaired containment of secondary infection, persistent macrophage and neutrophil activation, myofibroblast expansion, and uniform architectural destruction. This is not speculative storytelling. It is a mechanistic chain.
We no longer see the overwhelming waves of 2020. But the virus continues to circulate. Mortality in many regions has not returned cleanly to baseline. Unusual disease presentations persist — just not in dramatic surges. If CD147-mediated entry into immune cells contributes to immune depletion, repeated infections could theoretically increase susceptibility to opportunistic infections, promote fungal disease, reactivate latent viruses, or alter inflammatory patterns.
We do not have enough autopsies. We do not have enough deep immunophenotyping in unusual cases. And we are far too quick to declare the problem finished.
This transplant case may ultimately be unrelated to SARS-CoV-2. We do not have the full dataset. I have not accessed the complete paper. But the pattern described — diffuse inflammatory destruction, immune cell infiltration, fibrotic takeover — aligns with severe viral-mediated lung injury that failed to resolve.
The real issue is not whether this single case was “COVID.” The real issue is whether we are adequately investigating how a virus with potential backdoor immune access continues to shape disease presentation.
Because if the trapdoor exists, ignoring it will not close it. We are no longer in the acute emergency phase. We are in the long tail. And the long tail is where mechanistic clarity matters most.
Vejon COVID-19 Review is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
